Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease (2009)
- Authors:
- USP affiliated authors: FORLENZA, ORESTES VICENTE - FM ; GATTAZ, WAGNER FARID - FM
- Unidade: FM
- DOI: 10.1007/s00213-008-1351-0
- Subjects: COGNIÇÃO (TREINAMENTO); TRANSTORNOS COGNITIVOS (PREVENÇÃO E CONTROLE); DOENÇA DE ALZHEIMER; FOSFOLIPASES A (ATIVIDADE)
- Language: Inglês
- Imprenta:
- Source:
- Título: Psychopharmacology
- ISSN: 0033-3158
- Volume/Número/Paginação/Ano: v. 202, n. 1-3, p. 37-51, 2009
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SCHAEFFER, Evelin L. e FORLENZA, Orestes V. e GATTAZ, Wagner F. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology, v. 202, n. 1-3, p. 37-51, 2009Tradução . . Disponível em: https://doi.org/10.1007/s00213-008-1351-0. Acesso em: 27 dez. 2025. -
APA
Schaeffer, E. L., Forlenza, O. V., & Gattaz, W. F. (2009). Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology, 202( 1-3), 37-51. doi:10.1007/s00213-008-1351-0 -
NLM
Schaeffer EL, Forlenza OV, Gattaz WF. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease [Internet]. Psychopharmacology. 2009 ; 202( 1-3): 37-51.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1007/s00213-008-1351-0 -
Vancouver
Schaeffer EL, Forlenza OV, Gattaz WF. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease [Internet]. Psychopharmacology. 2009 ; 202( 1-3): 37-51.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1007/s00213-008-1351-0 - Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study
- A radioenzymatic assay to identify three groups of phospholipase A2 in platelets
- Interleukin-1β Serum Levels is Increased in Antidepressant-Free Elderly Depressed Patients
- Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study
- Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study
- Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients
- Long-Term Lithium Treatment Increases cPLA2 and iPLA2 Activity in Cultured Cortical and Hippocampal Neurons
- Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study
- Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression
- Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein
Informações sobre o DOI: 10.1007/s00213-008-1351-0 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
